According to the technical application, therapeutic mechanism and application prospect of therapeutic antibodies are discussed from the research and development of therapeutic antibodies to their application technology. Also, following is a list of some disadvantages of the drug. May this article shall lead perspective in the next section.
Vergote, I., Dean, E., Lassen, U., de Bono, J., Drew, Y., Machiels, J.-P., Nielsen, D., Arkenau, H.-T., Forster, M., Jones, R., Slomovitz, B., Spicer, J., Johnson, M., Cornez, N., Gennigens, C., Fulton, B., Lisby, S., Basse, L., Coleman, R. and Hong, D.S. (2017) A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients with Relapsed, Recurrent and/or Metastatic Cervical Cancer. Annals of Oncology, 28, V330-V331. https://doi.org/10.1093/annonc/mdx372.001
[4]
Nguyen Ngan, T.B., Lin, J., Tay, S.J., Mariati, Y.J., NguyenKhuong, T. and Yang, Y.S. (2021) Multiplexed Engineering Glycosyltransferase Genes in CHO Cells via Targeted Integration for Producing Antibodies with Diverse Complex-Type N-glycans. Scientific Reports, 11, Article No. 12969.
https://doi.org/10.1038/s41598-021-92320-x
He, K.F., Zeng, S. and Qian, L.H. (2020) Recent Progress in the Molecular Imaging of Therapeutic Monoclonal Antibodies. Journal of Pharmaceutical Analysis, 10, 397- 413. https://doi.org/10.1016/j.jpha.2020.07.006
于天维, 肖翌, 田海军, 潘琦, 陈应华. Purification of Murine Monoclonal IgM Antibody [J]. Tsinghua Science and Technology, 1999(3): 1532-1534.
[11]
Zhu, Z.P. and Yan, L. (2011) Next Generation of Antibody Therapy for Cancer. Chinese Journal of Cancer, 30, 293-302. https://doi.org/10.5732/cjc.011.10123
Sjöberg, R., Mattsson, C., Andersson, E., Hellström, C., Uhlen, M., Schwenk, J.M., Ayoglu, B. and Nilsson, P. (2016) Exploration of High-Density Protein Microarrays for Antibody Validation and Autoimmunity Profiling. New Biotechnology, 33, 582- 592. https://doi.org/10.1016/j.nbt.2015.09.002
